Biomarkers That Mislead

The testing market has an inversion problem: the tests it markets hardest are the ones with the least decision value, and the tests with the most value are too boring to sell. This page runs the ledger in both directions — the overrated premium tier, the honest niches where even those tests belong, and the underrated markers that deserve a place on more panels than they get.

The Test That Earns Its Slot

One rule runs this whole topic, and the parent page states it plainly: a test earns its place only if the result changes a decision. Every entry in the overrated column below fails that test for routine use — not because the science is fake, but because the number does not point anywhere. Every entry in the underrated column passes it for the price of a sandwich. The ledger follows.

Overrated: The Premium Tier

• 🧬 Biological-age clocks. The underlying science is genuine — DNA methylation patterns track chronological age across tissues (Horvath, Genome Biology, 2013), and composite clocks like PhenoAge associate with mortality (Levine et al., Aging, 2018). The commercial gap: retest variability is substantial, algorithms differ between vendors, and knowing "your biological age is 52, not 54" changes no decision that your actual risk factors have not already dictated. Science, yes; test you should buy, not yet.
• 🧲 Telomere-length kits. Telomere length is real biology, measured badly at retail: lab-to-lab technical noise is large relative to the changes the tests claim to track, and no action follows the number that would not follow from the free metrics anyway.
• 🌀 Whole-body MRI "cancer scans." The parent topic covers the core problem — incidental findings generate anxiety and cascading procedures, and there is no outcome evidence that routine full-body scanning helps. In a symptom-free person, most findings are benign, and the decision they change is usually "schedule more imaging."
• 🍞 IgG food-sensitivity panels. These measure IgG4 antibodies to foods and imply intolerance — but allergy societies have been explicit for years that IgG4 testing is not recommended for diagnosing food allergy or intolerance (Stapel et al., EAACI Task Force, Allergy, 2008). The gut complaints are real; the test does not explain them.
• ⚗️ Heavy-metal and "toxin" panels. Useful with a specific exposure — an old house, an industrial job, a known contamination — and false-alarm generators as routine screening. Everyone carries trace metals; the panel finds them and then sells you a detox.
• 🎢 Hormone snapshots. Testosterone, cortisol, and the rest pulse by the hour. Testosterone has a marked morning peak and declines across the day (Bremner, Vitiello & Prinz, JCEM, 1983), so a single afternoon draw says almost nothing about your level. "Adrenal fatigue" panels rest on a condition endocrinology societies do not recognize — the stress pillar covers cortisol honestly.

When the Same Test Is Worth It

The skip list is not a prohibition — it is an honesty requirement, and each overrated test has a defensible niche. A targeted MRI after a concerning finding is standard medicine. Testosterone testing makes sense with specific symptoms — fatigue, low libido, muscle loss — using two morning draws, interpreted under the Endocrine Society's guideline (Bhasin et al., JCEM, 2018), which anchors treatment to symptoms and repeated low values rather than a single number. Heavy-metal testing belongs to people with real exposures. The pattern: the test becomes worth it exactly when a reason precedes it — which is the tiered-panel logic from page one of this series.

Underrated: The Boring Tier

• 🧪 ApoB. Particle number is the cardiovascular measure with the cleanest causal evidence — genetic studies show lifetime exposure drives plaque, full stop (Ference et al., European Heart Journal, 2017). It costs about the price of dinner and still is not on many standard panels. The lipid-panel topic explains the particle math.
• 🧬 Lp(a). A genetically set, stable risk factor read once and factored forever (Tsimikas, JACC, 2017). For a one-time draw, it carries outsized lifetime context — arguably the most underpriced test on this page.
• 🩺 Urine albumin (uACR). The kidney early-warning line. Albumin in the urine rises before kidney function falls, and the KDIGO chronic kidney disease guideline builds risk staging around it — worth adding to any annual panel when diabetes or hypertension is in the picture (KDIGO, 2013).
• 🧭 ALT. A liver enzyme that costs pennies on a standard panel. A persistently rising ALT in someone who rarely drinks is a quiet flag for fatty liver — the fastest-growing liver problem in Western populations.
• 💪 Grip strength. Not a blood test at all — a handgrip dynamometer predicts outcomes better than many biomarkers. The exercise pillar's hidden-vital-signs topic has the norms and the science.
• 💓 CAC score, at the right moment. The exception that proves the imaging rule: at intermediate risk, a coronary calcium score changes the statin decision in both directions. The cadence and cost page covers the price and the timing.

When a Good Test Misleads: HbA1c

The ledger has a third column, and its best example is a test that belongs on every panel: HbA1c is excellent — except when it is quietly wrong. It reflects the previous two to three months of average glucose, which is its strength and its blind spot. Conditions that shorten red-cell lifespan — anemia, recent blood loss, some hemoglobin variants common in certain populations — can lower HbA1c independent of glucose, making control look better than it is. Rapid changes in glucose take months to show up, so early diabetes can hide behind a normal HbA1c while fasting glucose has already moved. Pregnancy changes the relationship entirely. The fix is not to distrust HbA1c; it is to read it as a pair with fasting glucose, the way the Glucose 101 topic recommends — each catches what the other misses, and disagreement between them is itself information.

The Ledger, Side by Side

Questions, Answered Briefly

• ❓ Is biological-age testing ever useful? As science and as curiosity, yes — the research is real and worth following. As a decision tool, not yet: the score changes nothing your actual risk factors have not already told you, and retest noise is high.
• ❓ My practitioner wants to run 50 markers — is that a problem? The count is not the sin; the decisions are. If most of the 50 answers would be "observe" regardless of the value, you are funding data collection. The Quarterly Audit blood-markers page shows what a decision-oriented panel actually looks like.
• ❓ What should I add to next year's panel? ApoB if it is missing, Lp(a) once, uACR with any metabolic risk, and the free functional tests — grip, balance, sit-to-stand. The Quarterly Audit protocol structures the whole rhythm.
• ❓ Do food-sensitivity panels explain my bloating? IgG panels do not diagnose intolerance — allergy societies have said so for years. A clinician-guided elimination and reintroduction remains the real tool, and the gut pillar covers the digestion side.

Related Topics